MAPK1 and head and neck squamous cell carcinoma: In head and neck squamous cell carcinoma, celecoxib upregulated ERK and/or p38 signaling and inhibited cell growth; when these ERK and/or p38 signaling pathways were blocked, the celecoxib-induced cell growth inhibition was significantly reversed [88].